In a series of QUICK GUIDES, we look at why the lateral flow diagnostics market is expected to grow by a Compound Annual Growth Rate (CAGR) of 8.2% by 2022, up from $5.5bn in 2017. (Source: MarketsandMarkets.com). We look at the growth of using lateral flow technology across the following areas:
- Edition I: Veterinary
- Edition II: Food safety and environmental testing [Read]
- Edition III: Infectious Disease [Read]
- Edition IV: Lateral flow quantification [Read]
Veterinary sector growth
By 2022, it’s expected that use of lateral flow technology in the veterinary sector will be worth $760m, a 2017-2022 CAGR of 7.1% (Source: MarketsandMarkets.com).*
Veterinary sector divides into:
- Companion animal: this area focuses on pets and domesticated animals and in 2017 equated to 69% of the rapid diagnostics market.
- Livestock animal: this area focuses on animals that are considered to be an asset. This area made up the rest of the rapid diagnostics market.
The migration to using rapid diagnostics, in general, is on the increase with the estimated 93,000 veterinarians in the U.S and nearly 200,000 veterinarians across EU countries leading the uptake in utilising rapid diagnostic methods.
Diagnosis for the following targets generates the highest revenue across rapid diagnostics market:
- Heartworm (Dirofilaria immitis)
- Feline leukaemia virus (FeLV)
- Feline immunodeficiency virus (FIV)
The following targets are also regularly tested for across the veterinary sector:
- Swine influenza
- Bovine leukaemia
- Newcastle disease
- Chicken anaemia virus
- Equine infectious anaemia
- Increased acceptance of point-of-care diagnostic solutions by veterinarians
- Increased willingness of pet owners to pay for animal health services either directly or through pet insurance
- Increased innovation in providing veterinary office diagnostic solutions
- Increased understanding of the impact of animal health on the food chain and human health (e.g. antimicrobial resistance)
- Increased acceptance from farmers of the benefits of near-animal testing, to allow early diagnosis to improve outcomes
- Increased evidence-based assessment (audit trail) of animal health and regulatory compliance either from Government or from the food industry or the consumer
Furthermore, lateral flow technology advancements, for example in conjugation methods and techniques, has allowed improvements in lateral flow performance e.g. increased sensitivity, which has increased the potential application of lateral flow technology in all markets, including the veterinary market.
Why does lateral flow fit the bill?
Lateral flow technology is already used in a wide number of applications within the animal health industry across both companion animal and livestock markets. The key reasons are:
- Simple to use
- Tried and Trusted Technology
- Flexible – Qualitative, Semi-Quantitative and Quantitative
- Multiplexing capabilities
Abingdon Health’s role in the growing lateral flow market
Abingdon Health has a long-track record of developing and manufacturing single target and multiplex lateral flow assays within regulated and non-regulated markets. Watch one of our videos or contact us to learn more about our capabilities.
*The COVID-19 crisis in 2020 accelerated the growth of lateral flow testing, with the market now projected to reach $10.2bn by 2025.